257 essays 1,087 funds measured independent · not paid by any fund or issuer we cover

Fund · iShares U.S. Pharmaceuticals ETF · measured from SEC filings

IHE holdings

IHE reports 58 holdings and behaves like 8.7 equally weighted ones, computed from its SEC Form N-PORT filing for 2026-06-30. The fact sheet publishes the first number; this page computes the second, and traces it across 28 quarters of filings.

Measured concentration

as of 2026-06-30

Read this figure with the following in mind

6.2% of net assets is securities-lending cash collateral, excluded from the figure; counted as filed the fund would read 8.4

The figure below is what the filing says, published unchanged. What it may not do is sit beside a plain long-only fund and be read as the same quantity. How comparability is decided.

58 Positions reported
8.7 Effective holdings
6.7× Concentration multiple
76.11% Top ten weight

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 6 issuer countries.

What stands out

as of 2026-06-30

IHE's largest investment is Johnson Johnson at 22.44% of net assets. ELI Lilly Co and Merck Co Inc follow; the three together are 49.24%. Ten companies are 76.11% of the fund; the other 48 share the rest. Among the 721 equity funds measured here, IHE behaves like 8.7 holdings against a median of 42.4 — 4.8 times more concentrated than the median. Across 28 quarterly filings IHE has held roughly steady since 2019-09-30 (8.6 then, 8.7 now). Between the 2026-03-31 and 2026-06-30 filings 3 positions were added and 2 dropped; 6.6% of the weight moved.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Every filing since 2019

28

Between 2019-09-30 and 2026-06-30, IHE went from behaving like 8.6 equally weighted positions to 8.7 — 1% more, while its top ten went from 79.18% to 76.11% of net assets. Read across the funds on the concentration-over-time table.

PeriodHoldingsEffective Top 10Largest
2026-06-30 58 8.7 76.11% 22.44%
2026-03-31 57 8.8 78.27% 23.03%
2025-12-31 56 8.3 77.73% 23.76%
2025-09-30 45 8.4 77.95% 23.16%
2025-06-30 38 8.4 79.01% 22.65%
2025-03-31 39 8.5 79.32% 22.47%
2024-12-31 43 7.8 80.51% 23.75%
2024-09-30 39 8.8 77.96% 22.09%
Earlier filings (20 more, back to 2019-09-30)
PeriodHoldingsEffectiveTop 10Largest
2024-06-30 38 8.1 79.75% 23.55%
2024-03-31 36 8.5 78.74% 22.35%
2023-12-31 35 9.1 76.89% 21.5%
2023-09-30 35 7.9 81.23% 23.65%
2023-06-30 42 8.1 78.36% 23.53%
2023-03-31 43 9.2 77.71% 22.85%
2022-12-31 44 9.7 75.03% 22.42%
2022-09-30 43 9.2 77.05% 23.52%
2022-06-30 43 8.8 78.51% 22.86%
2022-03-31 47 8.8 79.03% 22.52%
2021-12-31 47 8.2 80.91% 23.46%
2021-09-30 48 9.5 77.01% 22.33%
2021-06-30 49 9.8 76.7% 22.44%
2021-03-31 47 9.6 77.32% 23.11%
2020-12-31 45 9.8 77.02% 22.7%
2020-09-30 49 9.5 75.9% 22.35%
2020-06-30 45 9.9 75.68% 21.73%
2020-03-31 46 10.6 73.93% 20.16%
2019-12-31 47 9.5 75.71% 22.25%
2019-09-30 47 8.6 79.18% 22.69%

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

As filed, collateral included

6.24% collateral

IHE's filing lists 59 positions including 6.24% of net assets in securities-lending cash collateral. Counted as filed the fund reads 8.4 effective holdings with a top ten of 79.55%; on its own investments — the figure above — it reads 8.7 with a top ten of 76.11%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.

Largest positions, as filed

as of 2026-06-30

The 15 largest of 58 positions in IHE's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: IHE.csv.gz.

#PositionWeightCumulative
1JOHNSON & JOHNSON22.44%22.4%
2ELI LILLY AND COMPANY22.25%44.7%
3MERCK & CO., INC.4.55%49.2%
4BRISTOL-MYERS SQUIBB COMPANY4.37%53.6%
5ROYALTY PHARMA PLC4.34%57.9%
6VIATRIS INC.4.22%62.2%
7PFIZER INC.3.96%66.1%
8ZOETIS INC.3.73%69.9%
9JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY3.45%73.3%
10ELANCO ANIMAL HEALTH INCORPORATED2.81%76.1%
11AXSOME THERAPEUTICS, INC.2.42%78.5%
12CORCEPT THERAPEUTICS INCORPORATED1.90%80.4%
13LIGAND PHARMACEUTICALS INCORPORATED1.45%81.9%
14Definium Therapeutics Inc1.39%83.3%
15Liquidia Corp1.28%84.5%

By country of issuer

as of 2026-06-30

Share of IHE's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

CountryShare
United States 90.15%
United Kingdom 4.34%
Ireland° 3.78%
Canada 1.39%
Singapore 0.20%
Cayman Islands° 0.15%

Returns the fund reported

2019-07 – 2026-06

Monthly total returns from Item B.5 of IHE's own filings, 84 months on record. Not computed here and not from a price feed.

53.7%Last twelve months filed
121%Whole series, compounded
13.0%Best month
-9.3%Worst month

Cross-checked against a series computed separately from prices: median difference 0.06 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IHE.json · all funds.

Who borrows IHE's shares

2026-06-30

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $71m was out to 16 borrowers, 6.21% of net assets. The largest, JP MORGAN SECURITIES LLC, held 29.5% of it.

BorrowerOn loanShare of the loan
JP MORGAN SECURITIES LLC $21m 29.5%
National Financial Services LLC $10m 14.6%
BofA Securities, Inc. $10m 13.5%
GOLDMAN SACHS INTERNATIONAL $9m 12.0%
BNP PARIBAS SECURITIES CORP $4m 6.1%

Cash collateral reported against the loan: 6.24% of net assets, 100.4% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IHE has filed, with each borrower: IHE.json · all funds.

Since the previous filing

2026-03-31 → 2026-06-30

57 positions became 58: 3 added (0.8% of the fund at the later date), 2 dropped (1.3% at the earlier date). Half the sum of all weight changes, a turnover proxy: 6.6%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IHE compared this way, as a feed: changes.xml · all funds: filings received.

Largest increases2026-03-312026-06-30Largest decreases2026-03-312026-06-30
ELI LILLY AND COMPANY21.06%22.25% ZOETIS INC.4.52%3.73%
Definium Therapeutics Inc0.52%1.39% PFIZER INC.4.71%3.97%
CORCEPT THERAPEUTICS INCORPORATED1.05%1.90% JOHNSON & JOHNSON23.03%22.44%
Liquidia Corp0.72%1.28% ELANCO ANIMAL HEALTH INCORPORATED3.32%2.81%
AXSOME THERAPEUTICS, INC.2.00%2.42% ROYALTY PHARMA PLC4.70%4.34%
ORGANON & CO.0.44%0.81% PRESTIGE CONSUMER HEALTHCARE INC.0.78%0.51%

New: Veradermics Inc (0.56%), AtaiBeckley Inc (0.23%), XAV HEALTH CARE SEP26 (0.00%). Gone: Terns Pharmaceuticals Inc (1.27%), LENZ Therapeutics Inc (0.06%).

Asset categories and pricing

as of 2026-06-30

94.06% equity, 5.94% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

Derivative exposure and counterparties

as of 2026-06-30

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $1.14B. Notional of an interest-rate or currency swap is not equity exposure.

99.92%Stocks held directly
0%Swap notional (0)
0.05%Futures notional (1)
100%Sum, % of net assets

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Neighbours by effective holdings, equity funds

10

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IHE (8.7). Same filings, same arithmetic. Position in this list says nothing about which fund is better.

FundReportsBehaves likeTop tenAs of
EWY iShares MSCI South Korea ETF 84 6.3 69.83% 2026-05-31
ELM Elm Market Navigator ETF 18 6.7 90.37% 2026-06-30
XLSR State Street(R) US Sector Rotation ETF 29 7.2 88.52% 2026-06-30
EPU iShares MSCI Peru and Global Exposure ETF 34 8 73.44% 2026-05-31
EWS iShares MSCI Singapore ETF 20 8.2 80.68% 2026-05-31
AMLP Alerian MLP ETF 14 9.6 93.72% 2026-05-31
FLKR Franklin FTSE South Korea ETF 159 9.7 67.9% 2026-06-30
PSFF Pacer Swan SOS Fund of Funds ETF 13 9.7 92.19% 2026-07-31
XLY State Street(R) Consumer Discretionary Select Sector SPDR(R) ETF 50 9.8 69.18% 2026-06-30
DRSK Aptus Defined Risk ETF 23 9.8 97.18% 2026-07-31

Essays that examine IHE

0

Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.